Search Results

Displaying Results 1-16 of 16 "'NGM'"
Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight

May 27, 2026, 08:31 ET Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight

Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Novartis, Luxa Biotechnology, Gemini Therapeutics,

More news about: DelveInsight Business Research, LLP

Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito's UCNP imaging and Tethis' SmartBioSurface® slides

Mar 19, 2026, 06:37 ET Lumito and Tethis complete proof-of-concept study demonstrating compatibility between Lumito's UCNP imaging and Tethis' SmartBioSurface® slides

Division of Atomic Physics and Laser Centre. www.lumito.se The share is traded on NGM Nordic SME, under the name LUMITO and Mangold Fondkommission AB is Lumito's Mentor.About Tethis Tethis S.p.A. is a pioneering

More news about: Tethis S.p.A.

Eminent Signs Drill Contract for 10,000m RC Drill Program at HSRP

Mar 16, 2026, 06:30 ET Eminent Signs Drill Contract for 10,000m RC Drill Program at HSRP

https://s25.q4cdn.com/322814910/files/doc_downloads/operations/ngm/Turquoise-Ridge-Technical-Report-March2024.pdfDan McCoyCEO & DirectorWebsite: 

More news about: Eminent Gold Corp.

PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

Feb 10, 2026, 17:31 ET PROTAC Market Shows Accelerated Growth During the Forecast Period (2025-2034) Amid Rising Targeted Therapy Demand | DelveInsight

Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics, and others.

More news about: DelveInsight Business Research LLP

Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Feb 04, 2026, 17:31 ET Oncolytic Virus Clinical Trial Landscape Gains Momentum: 100+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics, and others.

More news about: DelveInsight Business Research, LLP

TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight

Feb 02, 2026, 17:31 ET TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight

Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics, and others.

More news about: DelveInsight Business Research, LLP

i-80 Gold Strengthens Board of Directors with the Addition of Ronald Butler Jr., Michael Jalonen, and Steven Yopps

Jan 29, 2026, 17:12 ET i-80 Gold Strengthens Board of Directors with the Addition of Ronald Butler Jr., Michael Jalonen, and Steven Yopps

Beatty district to establish a top-tier mining district in southern Nevada. Previously, Mr. Yopps was Manager of Growth Projects for Nevada Gold Mines ("NGM"), where he led the long-term processing and refractory ore transportation strategy following the Newmont–Barrick joint venture, multiple pre-feasibility

More news about: i-80 Gold Corp

Eminent Expands HSRP Claims in Key Area

Jan 13, 2026, 07:31 ET Eminent Expands HSRP Claims in Key Area

https://s25.q4cdn.com/322814910/files/doc_downloads/operations/ngm/Turquoise-Ridge-Technical-Report-March2024.pdf2

More news about: Eminent Gold Corp.

Eminent Intercepts 9.2m @ 3.2 g/t Au and Appoints Dan McCoy as President and CEO

Jan 06, 2026, 07:30 ET Eminent Intercepts 9.2m @ 3.2 g/t Au and Appoints Dan McCoy as President and CEO

https://s25.q4cdn.com/322814910/files/doc_downloads/operations/ngm/Turquoise-Ridge-Technical-Report-March2024.pdf*HSC001 aborted due to unusual drilling conditions at 21 metersON BEHALF OF THE

More news about: Eminent Gold Corp.

i-80 Gold Announces Lone Tree Plant Refurbishment Update; Study Highlights Material Increase in Margins and Short Payback Period

Dec 18, 2025, 19:05 ET i-80 Gold Announces Lone Tree Plant Refurbishment Update; Study Highlights Material Increase in Margins and Short Payback Period

14 years until being put on care and maintenance in 2007. It became part of NGM in July 2019 through the joint venture created between Barrick Mining and Newmont Corporation. i-80 Gold acquired the Lone Tree property from NGM in October 2021. Following the acquisition, the Plant remained on care and maintenance,

More news about: i-80 Gold Corp

Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight

Nov 24, 2025, 17:31 ET Short Bowel Syndrome Market to Register Stunning Growth at a CAGR of 5% During the Forecast Period (2025-2034) Owing to the Launch of Novel GLP-2 Analogues | DelveInsight

the market trends, market drivers, market barriers, and key IBS companies, including 4D pharma, Cosmo Pharmaceuticals, RedHill Biopharma Limited, NGM Biopharmaceuticals, among others.

More news about: DelveInsight Business Research, LLP

WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight

Nov 12, 2025, 17:31 ET WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight

Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, among others.

More news about: DelveInsight Business Research, LLP

Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight

Nov 04, 2025, 17:31 ET Cholestatic Pruritus Market is Predicted to Exhibit Remarkable Growth at a CAGR of 23.4% in the US During the Forecast Period (2025-2034) | DelveInsight

companies, including Gilead Sciences, Phenex Pharmaceuticals, HighTide Therapeutics, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., NGM Biopharmaceuticals, CymaBay Therapeutics, Chemomab Therapeutics, among others.

More news about: DelveInsight Business Research, LLP

Eminent Stakes Key Claims at HSRP as Drilling Progresses and New Targets Emerge

Oct 27, 2025, 07:03 ET Eminent Stakes Key Claims at HSRP as Drilling Progresses and New Targets Emerge

https://s25.q4cdn.com/322814910/files/doc_downloads/operations/ngm/Turquoise-Ridge-Technical-Report-March2024.pdf

More news about: Eminent Gold Corp.

Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight

Oct 23, 2025, 17:31 ET Mismatch Repair Deficiency Market Forecasts Strong Expansion During the Forecast Period (2025-2034) Driven by Rising Diagnostics and Immuno-Oncology Advances | DelveInsight

Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, among others.

More news about: DelveInsight Business Research, LLP

CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

Oct 01, 2025, 17:31 ET CXCR Inhibitors Market Set to Gain Momentum with Emerging Clinical Successes and Pipeline Expansion | DelveInsight

Alligator Bioscience, Bellicum Pharmaceuticals, OSE Immunotherapeutics, Actuate Therapeutics, FibroGen, NeoImmuneTech, NOXXON Pharma, Silenseed Ltd., Amgen, NGM Biopharmaceuticals, Merus, Mirati Therapeutics, Rexahn Pharmaceuticals, Ocuphire Pharma, Processa Pharmaceuticals, ImmunityBio, Berg, Panbela Therapeutics,

More news about: DelveInsight Business Research, LLP

Making a selection with these dropdown will cause content on this page to change. News search result will update as each option is selected.